General
Moderna to ask US and European regulators to allow emergency use of COVID-19 vaccine
Pharmaceutical company Moderna Inc. has said it will ask US and European regulators to allow emergency use of its COVID-19 vaccine, so that it can be widely distributed.
Key points:
- Results from a late-stage study show the vaccine was 94.1 per cent effective with no serious safety concerns
- Moderna said the shot was consistently effective across age, race, ethnicity and gender demographics
- US Food and Drug Administration advisers are scheduled to meet on December 17 to review the trial data
The company said full late-stage study results had confirmed the shots offered strong protection, and that its vaccine was 94.1 per cent effective, with no serious safety concerns.
It also reported a 100 per cent success rate in preventing severe cases.
Continue Reading
-
Business22 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Business23 hours agoHere’s a starter portfolio of ASX 200 shares to consider for growth, dividends, and value!
-
Noosa News22 hours agoThe Almond Ashes sees Australia and India mix business and cricket
-
General22 hours agoUK PM ready to ‘shelter’ businesses from tariff storm